Europe Pulmonary Arterial Hypertension Market Size & Outlook
Europe pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Europe pulmonary arterial hypertension market highlights
- The Europe pulmonary arterial hypertension market generated a revenue of USD 2,010.2 million in 2023.
- The market is expected to grow at a CAGR of 4.9% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Sweden is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 2,010.2 million |
| Market revenue in 2030 | USD 2,815.6 million |
| Growth rate | 4.9% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.2% of the global pulmonary arterial hypertension market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,501.9 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 46.82% in 2023. Horizon Databook has segmented the Europe pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Europe followed by North America held significant shares of around 21.1% share in 2020. The European Medicines Agency (EMA) and European Society of Cardiology have published guidelines for diagnosis and treatment of PAH. Moreover, these agencies are undertaking various awareness initiatives which facilitating early and preventive diagnosis.
Increasing prevalence of risk factors and associated diseases such as HIV is increasing the probability of development of PAH. An estimated 30 million people across Europe are suffering from rare diseases.
Increasing geriatric population, lifestyle changes and increasing pollution is anticipated to contribute towards increasing prevalence of PAH in Europe. In addition, players are undertaking initiatives to increase their foothold in the market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe pulmonary arterial hypertension market size, by country, 2018-2030 (US$M)
Europe Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
